Actively Recruiting
Study of Lumateperone to Improve Apathy in Adults with Schizophrenia or Related Psychotic Disorders
Led by Louisiana State University Health Sciences Center Shreveport · Updated on 2024-07-01
80
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether Lumateperone can improve motivation in adults aged 18 to 65 with schizophrenia or schizoaffective disorders who have high levels of apathy. The study also aims to see if changes in apathy relate to changes in symptoms measured by the Positive and Negative Syndrome Scale PANSS. This is a Phase 3 randomized clinical trial conducted with double masking to ensure unbiased results. Participants are randomly assigned to receive either a 42 mg capsule of Lumateperone once daily for 8 weeks or their existing antipsychotic medication reformulated into a capsule taken once or twice daily for the same period. The study compares these two treatments to assess their effects on motivation and psychotic symptoms. Treatment adherence and safety will be monitored throughout the 8-week intervention. During the study, participants will undergo assessments including the Apathy Evaluation Scale-Clinician AES-C and PANSS at baseline and after 8 weeks to measure changes in motivation and symptom severity. Other scales like the Brief Psychiatric Rating Scale BPRS will also be used. Researchers will analyze correlations between apathy and symptom changes. Participants must comply with scheduled visits and evaluations, and safety monitoring will continue throughout the trial, which is expected to conclude in December 2026.
CONDITIONS
Brief Title
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
Research Team
S
Shawn McNeil, MD
S
Stephanie Saunders, MA, CCRC
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here